A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
Get Instant Summarized Text (Gist) A therapeutic vaccine targeting HPV16 showed promise in reducing high-grade precancerous cervical lesions in a Phase II clinical trial. Among 18 patients with ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...
Opens in a new tab or window An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical ... in CIN3 lesion size in 17 ...
HealthDay on MSN6d
Therapeutic Vaccine Shows Preliminary Safety, Effectiveness for HPV16+ Cervical Precancerous ConditionFor patients with HPV16-positive CIN3, vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback